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Abstract
Vaginal HIV transmission accounts for the majority of new infections worldwide. Currently,
multiple efforts to prevent HIV transmission are based on pre-exposure prophylaxis with
various antiretroviral drugs. Here, we describe two novel nanoformulations of the reverse
transcriptase inhibitor rilpivirine for pericoital and coitus-independent HIV prevention. Topi-
cally applied rilpivirine, encapsulated in PLGA nanoparticles, was delivered in a thermosen-
sitive gel, which becomes solid at body temperature. PLGA nanoparticles with
encapsulated rilpivirine coated the reproductive tract and offered significant protection to
BLT humanized mice from a vaginal high-dose HIV-1 challenge. A different nanosuspen-
sion of crystalline rilpivirine (RPV LA), administered intramuscularly, protected BLT mice
from a single vaginal high-dose HIV-1 challenge one week after drug administration. Using
transmitted/founder viruses, which were previously shown to establish de novo infection in
humans, we demonstrated that RPV LA offers significant protection from two consecutive
high-dose HIV-1 challenges one and four weeks after drug administration. In this experi-
ment, we also showed that, in certain cases, even in the presence of drug, HIV infection
could occur without overt or detectable systemic replication until levels of drug were
reduced. We also showed that infection in the presence of drug can result in acquisition of
multiple viruses after subsequent exposures. These observations have important implica-
tions for the implementation of long-acting antiretroviral formulations for HIV prevention.
They provide first evidence that occult infections can occur, despite the presence of sus-
tained levels of antiretroviral drugs. Together, our results demonstrate that topically- or sys-
temically administered rilpivirine offers significant coitus-dependent or coitus-independent
protection from HIV infection.
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Author Summary
When taken consistently, PrEP has been shown to reduce the risk of HIV infection by up
to 92% in people who are at high risk. However, PrEP is much less effective if it is not
taken consistently. To improve adherence to the drug regimen, several new drug delivery
systems, that include novel gel formulations and long-acting delivery systems, are being
evaluated. In this manuscript, we used BLT humanized mice, an in vivomodel of vaginal
HIV transmission, to evaluate two novel delivery systems for HIV prevention. In the first
approach, we combined the highly efficient encapsulation of antiretroviral drugs into
nanoparticles with a thermosensitive gel that remains liquid at room temperature and
solidifies at body temperature. Our results showed that this delivery system provided sig-
nificant protection from HIV vaginal infection. In a second approach, we evaluated a
long-acting nanoparticle formulation for coitus-independent protection from HIV acqui-
sition. Our results showed that a single injection of the long-acting antiviral drug also
resulted in reduced HIV infection. However, protection was not complete and transmis-
sion was concealed by a significant delay in the onset of plasma viremia that could result
in superinfection by two different viruses administered up to four weeks apart.
Introduction
Although the annual number of new HIV infections continues to decline, the global HIV-1
pandemic remains an unprecedented public health problem, with 2.1 million new infections in
2013 and an estimated 35 million people already infected [1]. This highlights the urgent need
for effective and safe prevention strategies for HIV infection. With the continued absence of an
effective vaccine, the efficacy of various antiretrovirals (ARVs) has been evaluated as pre-expo-
sure prophylaxis (PrEP). HIV PrEP refers to the strategy of using ARV drugs to decrease the
risk of HIV infection in uninfected individuals who are at high risk of infection. Multiple clini-
cal trials, including the CAPRISA 004, the Chemoprophylaxis for HIV Prevention in Men
(iPrEx), the Partners PrEP, and the TDF2 studies have shown that topical or oral pre-exposure
administration of ARVs reduces the risk of HIV-1 infection by 39 to 75% [2–5]. Overall effi-
cacy, as well as low rates of protection in some trials, correlates with adherence to the dosing
regimen [3]. To improve adherence and PrEP efficacy, several strategies are being considered.
These include effective antiretrovirals, easily administered in single topical or systemic dose
pericoitally, and long-acting ARV formulations that release drugs over many weeks systemi-
cally, requiring infrequent parenteral administration [6–8].
Rilpivirine (RPV, TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI), is a
diarylpyrimidine derivative that inhibits HIV reverse transcriptase by binding to a hydropho-
bic pocket near the active site of the enzyme, and consequently preventing transcription of
viral RNA. RPV has activity against wild type and many NNRTI-resistant HIV-1 strains [9].
Although RPV has an excellent profile for HIV prevention, there is currently no information
regarding the effectiveness of oral RPV for HIV prevention, and no RPV formulations for topi-
cal use have been described. Recently, a long-acting crystalline nanoparticle suspension of RPV
(RPV LA) has been developed, with the objective of providing drug exposure over extended
periods of time following intramuscular administration [10]. A single intramuscular injection
of RPV LA provided sustained release of RPV into plasma over 3 months in dogs, 2 months in
rats, and 3 weeks in mice [10, 11]. In humans, a single intramuscular administration of RPV
LA leads to substantial levels of RPV in plasma, cervico-vaginal fluid and vaginal tissue for 84
Topical and Systemic Antiretrovial Nanoformulations for HIV Prevention
PLOS Pathogens | DOI:10.1371/journal.ppat.1005075 August 13, 2015 2 / 19
study design, data collection and analysis, decision to
published, or preparation of the manuscript.
Competing Interests: I have read the journal's policy
and the authors of this manuscript have the following
competing interests: GK, SLD and PW are employed
by Janssen Research and Development, LLC. This
does not alter our adherence to all PLOS policies on
sharing data and materials. Other authors have
declared that no competing interests exist.
days. RPV levels measured at multiple sites of HIV transmission suggest a potential role for
RPV LA as coitus-independent PrEP in humans [10, 12].
Animal models are essential to the effective evaluation of new HIV prevention strategies. For
example, rhesus macaques (Macaca mulatta) and pigtail macaques (Macaca nemestrina) were
recently used to test whether a long acting formulation of an integrase inhibitor could prevent
transmission of HIV via rectal or vaginal routes [13–15]. However, the species-specific tropism
of HIV prevents the evaluation of relevant viruses, including transmitted/founder viruses, for in
vivo challenges in these models [16, 17]. Instead, chimeric simian/human immunodeficiency
viruses (SHIVs) must be used. Here we tested the efficacy of a topical pericoital and a long-act-
ing systemic nanoformulation of RPV to prevent vaginal HIV-1 transmission using humanized
bone marrow/liver/thymus mice (BLT). BLT mice are immunodeficient mice individually bio-
engineered to express a de novo-generated human immune system distributed throughout each
animal [18–21], allowing infection with a variety of transmitted/founder HIV-1 isolates via rele-
vant routes of transmission. The mouse female reproductive tract (FRT) has anatomic similari-
ties to that of humans, despite its smaller size and presence of two uterine horns that merge to
form the main body of uterus. The murine vagina and ectocervix are covered with stratified
squamous epithelium, whereas the endocervix and uterus consist of a simple columnar epithe-
lium. The physical barrier that HIV would encounter is, therefore, somewhat similar to that in
humans [22]. We previously demonstrated the presence of human CD4+ T cells, macrophages
and dendritic cells throughout the mouse female reproductive tract (FRT), that render BLT
mice susceptible to vaginal HIV-1 transmission [23, 24]. Both topical and systemic HIV preven-
tion interventions, which parallel human clinical trials, have been successfully performed in
BLTmice [23, 25–28]. These studies validate BLTmice as a suitable model for the evaluation of
novel or improved drug formulations for the prevention of HIV transmission.
Results
Approach for the evaluation of new RPV formulations for the prevention
of vaginal HIV infection in humanized BLT mice
We used humanized BLT mice to test two different strategies to prevent vaginal HIV transmis-
sion by RPV. Each strategy used a distinct nanotechnology formulation of RPV. RPV gel, a
potential pericoital microbicide (developed at Creighton University, Omaha, Nebraska USA),
was applied to the vaginal mucosa in single doses 1.5h or 24h before HIV challenge (Fig 1A).
In other studies, a coitus-independent, systemic long-acting formulation of rilpivirine RPV LA
(developed by Janssen Research and Development, Beerse, Belgium), was administered intra-
muscularly, 1 week before HIV-1 challenge (Fig 1B). The presence of plasma viral RNA was
monitored over time as an early indication of infection. At the end of these experiments, multi-
ple tissues were analyzed for the presence of cell-associated viral DNA. Only animals treated
with RPV nanoformulations, and negative for both viral RNA and DNA in peripheral blood
and tissues, were considered protected from vaginal HIV-1 transmission.
RPV, encapsulated in PLGA nanoparticles and delivered in a
thermosensitive gel, inhibits HIV-1 infection in vitro
The majority of clinical trials evaluating pericoital HIV prevention approaches, including
CAPRISA 004, used conventional gels for vaginal microbicide delivery. However, such gels have
major disadvantages, including gel leakage, uneven distribution, and messiness, which can
decrease adherence to the dosing regimen [29]. To overcome these potential drawbacks, we for-
mulated poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with RPV (PLGA/RPV NP),
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in a thermosensitive gel which is liquid at room temperature but highly viscous at body temper-
ature. This property minimizes chances of gel leakage. Moreover, as reported previously, ther-
mosensitive pluronic gels are insensitive to dilution by simulated vaginal fluid [30–33]. PLGA
NPs are US FDA-approved biodegradable particles, which can encapsulate ARV and provide
their sustained release [34–38]. PLGA/RPV NPs were prepared by emulsion-solvent evapora-
tion. Average particle size was 66.0 ± 4.2nm (mean ± SEM, n = 3) measured by dynamic light
scattering, which was further validated using Scanning ElectronMicroscopy (Fig 2A). The aver-
age polydispersity index was 0.14 ± 0.05, zeta potential of the NPs was -10.96 ± 1.4mV
(mean ± SEM, n = 3). The RPV encapsulation efficiency in the polymeric nanoparticle, deter-
mined by an indirect method as described in the Materials and Methods section, was 98 ± 0.7%
and the RPV loading in nanoparticles was ~ 5% w/w of polymer. As shown in Fig 2B, the intra-
cellular uptake of RPV by HeLa cells cultured in presence of a 5μg/ml RPV solution or in the
presence of 5μg/ml RPV in PLGA/RPV NPs, was comparable. In TZM-bl indicator cells,
PLGA/RPV NPs showed similar in vitro inhibition of HIV-1 infection as RPV in solution (Fig
2C). Together, these data confirmed the potential of PLGA/RPV NPs to effectively deliver ARV
to target cells. For in vivo evaluation in BLT humanized mice, PLGA/RPV NPs were formulated
into a previously characterized thermosensitive gel containing Pluronic F127 and Pluronic F68
[32]. The concentration of RPV in thermosensitive gel was 0.876mg/ml.
Distribution of PLGA/RPV nanoparticles in thermosensitive gel in the
female reproductive tract of BLT mice and prevention of vaginal HIV
acquisition after vaginal administration
In humans, cervicovaginal mucus is a significant barrier and clearance mechanism that limits
vaginal drug delivery and retention. To achieve sustained drug release and maintain protective
drug concentrations during pre-exposure prophylaxis, drug-loaded nanoparticles need to
Fig 1. Experimental design for the evaluation of efficacy of RPV nanoformulations in prevention of vaginal HIV transmission in humanized BLT
mice. (A) Experimental design for evaluation of efficacy of PLGA nanoparticles loaded with RPV (PLGA/ RPV NPs) in thermosensitive gel as a pericoital
PrEP administered as a single topical application 1.5 h or 24 h before HIV-1 challenge. (B) Experimental design for evaluation of efficacy of long acting
nanosuspension of RPV administered in a single dose intramuscularly 1 week before HIV-1 challenge, as a coitus-independent approach to prevent vaginal
HIV transmission.
doi:10.1371/journal.ppat.1005075.g001
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penetrate cervicovaginal mucus and be efficiently distributed across the female reproductive
tract [39]. The ability of PLGA/RPV NPs in thermosensitive gel to distribute in the FRT of
humanize mice was evaluated using rhodamine-labeled PLGA NPs. Rhodamine-labeled PLGA
NPs in thermosensitive gel were instilled into the mouse vagina and their presence and locali-
zation was assessed by confocal microscopy. Ninety minutes after vaginal administration, the
fluorescence signal was seen as a continuous layer at the luminal site of the vaginal epithelium.
Interestingly, some fluorescence, although with much lower intensity, was still found on the
Fig 2. In vitro characterization of PLGA/RPV NPs in thermosensitive gel. (A) Scanning electron
microscope image of PLGA/RPV nanoparticles. (B) RPV uptake by HeLa cells. Cells were incubated with
5 μg/ml RPV in solution or in the PLGA/RPV NP formulation. Intracellular RPV and RPV in medium were
analyzed by HPLC (n = 3). (C) In vitro analysis of the inhibition of HIV infection by PLGA/ RPV NPs. TZM-bl
HIV indicator cells were treated with the indicated concentrations of RPV solution or PLGA/RPV NPs. Cells
were challenged with HIV-1NLX 24 h after RPV treatment. Infection of cells was evaluated by ONE-Glo assay
48 h post infection (n = 3). Data were normalized to luminescence of untreated cells (100%); p = 0.0963.
doi:10.1371/journal.ppat.1005075.g002
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vaginal epithelium 24h after administration. Fluorescence signals were also observed deeper in
the tissue in close proximity of hCD45, hCD3, hCD4, hCD8, and hCD11c cells (Fig 3A and
3B). Given the stability of Rhodamine encapsulation in this type of nanoparticles [40], these
results demonstrate that PLGA nanoparticles, delivered in thermosensitive gel, can reach the
vaginal epithelium and the location of HIV target cells, and persist for 24h.
To test the effectiveness of PLGA/RPV NPs in preventing HIV-1 vaginal transmission,
humanized BLTmice were topically treated with PLGA/RPV NPs in thermosensitive gel (20μl
of gel, 17.5μg of RPV per mouse; n = 12), thermosensitive gel containing PLGA NP without
RPV, or vehicle (n = 8). Treated animals were challenged 1.5h (n = 4) or 24h (n = 8) after gel
application with a high dose of HIV-1RHPA, a CCR5-tropic transmitted/founder virus (3.1×10
5
TCID) [16]. The presence of plasma viral RNA in peripheral blood was determined at intervals
thereafter. No plasma viral RNA was found in the peripheral blood of any of the animals chal-
lenged with HIV-1 1.5h after the administration of PLGA/RPV NPs in thermosensitive gel (0/4)
nor in 4/8 of the animals that received PLGA/RPVNPs in thermosensitive gel 24h prior to expo-
sure to HIV-1 (p = 0.0084 and p = 0.0582 respectively). Seven to eight weeks post-exposure,
cells isolated frommultiple organs were analyzed for the presence of viral DNA. The lack of
detectable cell-associated viral DNA in tissues confirmed the absence of HIV infection in these
animals (Fig 3C–3E, S1 Table). The presence of plasma viral RNA and cell-associated viral DNA
in peripheral blood and tissues of all the control mice confirmed efficient HIV transmission (Fig
3C and 3D). The protection of all BLT mice challenged with HIV-1 1.5h after treatment with
PLGA/RPV NPs in thermosensitive gel, and the protection of 50% of the mice treated 24h prior
to challenge with HIV-1, demonstrated the effectiveness of PLGA/RPV NPs in HIV prevention.
Administration of a single dose of RPV LA results in sustained plasma
levels of drug
To evaluate the efficacy of a coitus-independent systemic RPV LA formulation to prevent
HIV-1 infection, we first determined the plasma RPV concentrations in mice for 28 days after
intramuscular injections of either 15mg (50μl of 300mg/ml RPV LA nanosuspension) or 7.5mg
(25μl of 300mg/ml RPV LA nanosuspension) of RPV LA (n = 4 per group). As shown in Fig
4A, high levels of RPV were detected in the plasma of all treated animals 24h post-injection.
Plasma drug levels decreased rapidly over the following 4 days. After this point, the levels of
RPV in plasma remained relatively constant for 10 days and then decreased gradually over the
next two weeks. Throughout the 28 days of the study, RPV plasma levels exceeded the protein-
adjusted IC90 of 12ng/ml [41]. These results demonstrated that a single intramuscular injection
of RPV LA resulted in sustained levels of drug in plasma in mice and established its potential
to serve as a prevention strategy for intermittent use.
A single administration of RPV LA efficiently prevents HIV-1 infection in
BLT humanized mice
BLT mice (n = 12) were injected intramuscularly with 15mg of RPV LA (n = 6), vehicle or left
untreated (n = 6). One week later, mice were challenged vaginally with a high dose (3.5×105
TCID) of HIV-1CH040, a transmitted/founder virus [17]. Viral RNA in plasma was evaluated
over the following 8 weeks. Five out of six control mice were infected within 2 weeks after chal-
lenge, as evidenced by the presence of viral RNA in plasma. In sharp contrast, no viral RNA
was detected in the plasma of the animals treated with RPV LA (Fig 4B, S2 Table). Analysis of
tissue DNA of RPV LA-treated mice demonstrated the absence of viral DNA in all samples
analyzed (S2 Table, Fig 4C). These results demonstrated that a single administration of RPV
LA 7 days prior to challenge offered significant protection from vaginal HIV-1CH040 infection.
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Fig 3. Distribution of rhodamine-labeled NPs in thermosensitive gel in the mouse female reproductive
tract (FRT) and the ability of PLGA/RPV to offer pericoital protection against HIV-1 transmission. (A, B)
Distribution of rhodamine-labeled PLGA nanoparticles in transverse sections of mouse FRT. Nanoparticles in
thermosensitive gel were administered vaginally to humanized BLT mice. FRT was isolated and processed at
indicated times and sections were stained for hCD45 (A), hCD3, hCD4, hCD8, hCD11c (B) and DAPI (A, B).
Control nanoparticles contain only PLGA. Scale bar = 100 μm. Arrowheads are showing nanoparticles in
tissue, arrows are showing nanoparticles on the edge of vaginal epithelium. (C, D) Protection of BLT mice
from vaginal HIV-1 infection by topically applied thermosensitive gel containing PLGA/RPV NPs (20 μl of gel,
17.5 μg of RPV per mouse). Controls were treated with vehicle or with thermosensitive gel containing blank
NPs. Mice were exposed vaginally to HIV-1RHPA 1.5 h (n = 4) (C) or 24 h (n = 8, two independent
experiments) (D) after vaginal administration of gels. Viral RNA was quantified by real time PCR (RT PCR)
with a limit of quantitation (LOQ) of 400 copies of RNA per ml (dotted line); graphs represent means ±SD. (E).
Kaplan-Meier plots representing the percentage of BLT mice protected by PLGA/RPV NPs in
thermosensitive gel over time until the first peripheral blood viral RNA detection. Protected animals were
negative for viral RNA in plasma as well as viral DNA in tissue analyzed after necropsy. Statistical analysis:
Log-rank (Mantel-Cox) test; controls vs. 1.5 h p = 0.0084, controls vs. 24 h p = 0.0582
doi:10.1371/journal.ppat.1005075.g003
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It should be noted that longitudinal flow cytometry analysis of the mouse peripheral blood con-
firmed that the absence of viral RNA and DNA in the mice treated with RPV LA and exposed
to HIV-1CHO40 was not due to a loss or to reduced levels of human CD45
+ cells or human CD3-
+CD4+ cells throughout the course of the experiment. Only in the infected mice were we able
to demonstrate a gradual decrease in the levels of human CD3+CD4+ cells (Fig 4D).
Efficacy of RPV LA in preventing HIV infection after two high dose
challenges by different HIV isolates 1 and 4 weeks after drug
administration
The overall experimental approach to evaluate the ability of RPV LA to prevent vaginal HIV
transmission after two high dose challenges is shown in Fig 5A. BLT mice received a single
Fig 4. Ability of RPV LA to offer coitus-independent protection from vaginal HIV-1 transmission in BLTmouse. (A) Longitudinal analysis of RPV
levels in plasma of NSGmice injected intramuscularly once with 7.5 mg or 15 mg RPV LA (n = 4 for each group, dotted line indicates IC90). (B) Plasma viral
RNA in BLT mice challenged vaginally with HIV-1CH040 (3.5×10
5 TCID), a transmitted/founder virus 1-week post administration of RPV LA (15 mg, n = 6) or
vehicle (n = 6) intramuscularly. Shown are plasma viral RNA (dotted line-LOQ 400 copies of RNA per ml of plasma). (C) Kaplan-Meier plots representing the
percentage of BLT mice protected from HIV transmission by RPV LA as a function of the number of weeks post challenge until the first peripheral blood viral
RNA detection. Protected animals were negative for viral RNA in plasma and viral DNA in tissue analyzed after necropsy (P = 0.0047, Log rank/Mantel Cox
test). (D). Human CD45 cell levels in peripheral blood (percent of total live cells) and human CD4 levels (percent of human CD3 positive cells) were analyzed
by flowcytometry at the indicated times. Solid lines: RPV LA treated mice, dashed lines: control animals.
doi:10.1371/journal.ppat.1005075.g004
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15mg intramuscular injection of RPV LA (n = 10) or vehicle (n = 4). Mice were challenged one
week later with a high dose of either HIV-1JR-CSF [an early passage CCR5-tropic primary iso-
late] (n = 3, TCID 3.5×105), HIV-1CH040 (n = 4, TCID 3.5×10
5) or HIV-1RHPA (n = 3, TCID
3.1×105) transmitted/founder CCR5-tropic viruses. Control mice were challenged with HIV-
1CH040 or HIV-1RHPA (n = 2 each). Plasma viral RNA was monitored over time. Viral RNA was
detected in 4/4 of the control mice. Two weeks post-challenge, no viral RNA was detected in
any of the animals that received RPV LA (Fig 5b, S2 Table). Four weeks after RPV LA adminis-
tration (3 weeks after the first challenge), mice were challenged vaginally with HIV-1THRO, a
different CCR5-tropic transmitted/founder virus (TCID 3.5×105), in parallel with 6 additional
control (no drug) BLT mice (also challenged with HIV-1THRO). Mice were monitored for the
presence of plasma viral RNA for an additional 5 weeks. Seven of ten RPV LA-treated mice
became infected within 4 weeks after the second HIV-1 challenge. In order to identify the virus
that resulted in the infection of the RPV LA-treated mice, plasma viral RNA from each infected
mouse was sequenced. Sequence analysis revealed that, despite the fact that no viral load was
detected in plasma for over 2 weeks after the first challenge, 2 of these mice had actually
acquired infection from the first challenge. A third mouse acquired infection after both chal-
lenges (dually infected mouse). Sequence analysis of the other 4 mice showed that they were
only infected with the second challenge virus (Fig 5B, S1 Fig, S3 Table). No mutations associ-
ated with RPV resistance were found in the virus present in any of the RPV LA-treated and
infected mice. Analysis of DNA from tissues of the three remaining uninfected mice treated
with RPV LA revealed the absence of viral DNA in all tissues analyzed and confirmed their
protection from HIV transmission after two high dose challenges (Fig 5C). In summary, during
the dual challenge experiment, 7/10 RPV LA-treated animals were protected from the first
challenge and 4/9 from the second challenge. These results demonstrate that RPV LA offered
significant (>80%; p<0.0001) protection from a high dose of virus administered one week
later, and partial (44%; p = 0.0038) protection from a second high dose HIV challenge 4 weeks
after drug administration.
Discussion
There have been numerous attempts to prevent HIV infection with the topical application of
microbicides [42]. Topical PrEP is based on the premise that blocking HIV at the site of entry
offers the best opportunity to prevent HIV infection and avert systemic toxicity. Topical appli-
cation of non-specific HIV inhibitors has failed to show protection against HIV infection in
several large clinical trials [43]. In contrast, the first clinical trial, evaluating the potential of
tenofovir in a vaginal gel formulation (CAPRISA 004), demonstrated significant protection [2].
Subsequent trials, using topically applied tenofovir, were not able to demonstrate protection,
most likely due to a lack of product use [44, 45]. Here, we evaluated the efficacy of RPV formu-
lated in PLGA nanoparticles suspended in a thermosensitive gel that remains liquid at room
temperature but solidifies at body temperature. We evaluated the distribution of nanoparticles
in the vagina of BLT mouse using PLGA nanoparticles with encapsulated rhodamine as a sur-
rogate for rilpivirine. We chose rhodamine because it had been previously shown to be released
slowly from the PLGA nanoparticles, with initial burst release seen in the first several hours fol-
lowed by a more sustained, uniform release [40]. Our results showed that rhodamine-PLGA
NPs formed a layer on the lumen of the vaginal epithelium. Some of the particles persisted at
the vaginal epithelium 24h post-administration. However, PLGA NPs also infiltrated into the
tissue, as fluorescence signal was also found in close proximity to HIV target cells. BLT mice,
vaginally treated with PLGA/RPV NPs in the thermosensitive gel, were protected against a
high dose challenge with a transmitted/founder virus administered 1.5h later. Protection,
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diminished (by 50%) when BLT mice were challenged 24h after gel administration. These
results demonstrated that topical administration of this novel PLGA/RPV NP thermosensitive
gel formulation efficiently prevented vaginal HIV transmission in this animal model.
An alternative to topical PrEP is the systemic administration of antiretrovirals for the pre-
vention of HIV acquisition. The results from multiple clinical trials (iPrEx, TDF2 and Partners
PrEP study) demonstrate that systemic PrEP can prevent HIV acquisition via rectal and vagi-
nal exposure [3–5]. The results from virtually all clinical trials of HIV prevention using antire-
trovirals demonstrate that efficacy depends on product usage. Long-acting injectable
Fig 5. Analysis of RPV LA protection after exposure to high doses of multiple transmitted/founder
viruses and an early passage primary isolate. (A) Experimental design. BLT mice were challenged with
CH040, RHPA or JR-CSF HIV-1 isolates 1 week after RPV LA administration. Four weeks after RPV LA
administration, mice were challenged again, but this time with HIV-1THRO, a transmitted/founder virus. (B)
Plasma viral load in RPV LA treated BLT mice (n = 10) and controls (n = 4 for 1st challenge, n = 6 for 2nd
challenge). Dash line indicates LOQ. Data are presented as mean ± SD. (C) Kaplan-Meier plots representing
the percentage of BLT mice protected against HIV transmission by RPV LA intramuscular injection as a
function of the number of weeks post 1st and 2nd challenges until the first peripheral blood viral RNA
detection. Arrows in panels (B) and (C) indicate time of 1st and 2nd challenges. RHPA (n = 2) and CH040
(n = 2) were used as controls for the first challenge (Control 1); for the 2nd challenge, all control animals were
exposed to THRO (n = 6; Control 2); RPV LA indicates RPV LA treatment. Statistical analysis: Log-rank
(Mantel-Cox) test, 1st and 2nd challenge were analyzed separately, controls 1 vs. 1st challenge p = <0.0001,
controls 2 vs. 2nd challenge p = 0.0038.
doi:10.1371/journal.ppat.1005075.g005
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formulations of antiretrovirals are one of several approaches that are being considered to
enhance adherence to preventive measures.
GSK744 (Cabotegravir) LA is an injectable nanosuspension formulation of an integrase
inhibitor that has been shown to be safe and to sustain adequate levels of drug when adminis-
tered intermittently. Recent results from investigations in non-human primates also demon-
strate that GSK744 LA can efficiently prevent infection after repeated low dose viral challenges
[13–15]. However, it should be noted that this formulation has demonstrated lower efficacy at
preventing infection after a high dose challenge [14].
RPV LA is a long-acting injectable nanosuspension formulation of the NNRTI rilpivirine.
Sustained levels of RPV in plasma after single intramuscular injection of RPV LA were
reported in dogs, rats and mice, and in plasma, cervico-vaginal fluid and vaginal tissue of
humans [10, 12]. However, an assessment of RPV LA in preventing HIV-1 vaginal transmis-
sion in a relevant animal model has not yet been reported. Here, we showed that a single
administration of RPV LA in BLT mice conferred significant protection against a high dose
vaginal challenge with HIV-1 one week after drug administration. Our results also demon-
strated that a single administration of RPV LA offered protection, albeit reduced, from a sec-
ond virus challenge 1 month after drug administration. Importantly, while all our control mice
were infected within 2 weeks after challenge, breakthrough infections in treated animals were
delayed and occurred 3 weeks after first challenge (4 weeks after drug administration) or 2–4
weeks after second challenge (6–8 weeks after drug administration). These results are consis-
tent with a model in which the initial infection occurs at the site of exposure, but is contained
by the presence of sustained levels of drug, preventing systemic replication. Once the levels of
drug are unable to efficiently inhibit virus replication, viral spread can occur. Due to faster
clearance in mice, a sustained level of RPV in plasma after single injection of RPV LA lasts sig-
nificantly longer in humans than mice (3 months in humans vs. 3 weeks in mice, [10, 11]).
Therefore, it is reasonable to anticipate a longer protective effect of RPV LA in humans. In
summary, our results in humanized BLT mice highlight the potential of RPV as a candidate for
HIV pre-exposure prophylaxis in both a topical coitus-dependent thermosensitive gel formula-
tion as well as in a long acting injectable nanosuspension.
Materials and Methods
Preparation and characterization of RPV-loaded PLGA nanoparticles
Resomer 752 H (acid terminated poly-lactic-co-glycolic acid; Avg. Mol. Wt. 15000Da) was pur-
chased from Sigma Chemicals (St. Louis, MO, USA). Rilpivirine (RPV) was purchased from
Sequoia Research Ltd. (Pangbourne, UK). Potassium dihydrogen phosphate (HPLC grade),
acetonitrile (HPLC grade), dimethyl sulfoxide (DMSO, AR Grade), ethyl acetate (AR grade),
citric acid (AR grade) and trisodium citrate (AR grade) were purchased from Fisher Scientific
Ltd (NJ, USA). Pluronic F127 and Pluronic F68 (BASF, NJ, USA) were received as gift samples.
The ultra-pure water was obtained for all the experiments with the use of PURELAB Ultra sys-
tem (Elga LLC, IL, USA).
RPV-loaded PLGA nanoparticles were prepared using a previously described emulsion-sol-
vent evaporation method [46]. Briefly, Resomer 752H (200mg) and Pluronic F127 (200mg)
were dissolved in 3ml ethyl acetate by heating at 40°C in an incubating shaker bath. RPV
(10mg) was dissolved in DMSO (50μl) by heating at 40°C in an incubating shaker bath and
then transferred to the Resomer 752H solution to obtain a homogenous organic phase. The
organic phase was added drop-wise to 10ml ultrapure water and homogenized using a probe
sonicator (UP100H; Hielscher USA, Inc., NJ, USA). The resultant oil-in-water emulsion was
stirred for 4h using a magnetic stirrer. Due to the photosensitive nature of RPV, the contents in
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the beaker were protected from light during the evaporation of ethyl acetate. The mean particle
size, polydispersity index and zeta potential of the PLGA/RPV nanoparticles were measured in
triplicate using dynamic light scattering at an angle of 90° at 25°C, by a “ZetaPlus” Zeta Poten-
tial Analyzer (Brookhaven Instruments Corp, NY, USA). For fabricating rhodamine-6G-
labeled fluorescent PLGA nanoparticles, RPV was replaced with rhodamine-6G (1mg) and
nanoparticles were formulated as described earlier.
SEM imaging of nanoparticles. For SEM imaging, PLGA/RPV NPs (~ 30μl) were trans-
ferred onto two-sided conductive tape (PELCO Tabs, 12mm OD, TED PELLA, Inc, Redding,
CA) mounted on a aluminum stub. PLGA/RPV NPs were air-dried for>24h and sputter-
coated with palladium under an argon gas atmosphere, using a Denton Desk V HP TSC Sput-
ter Coater (Denton Vacuum, LLC-USA, Moorestown, NJ). The coated NPs were examined
using a Hitachi S4700 field-emission Scanning Electron Microscope (SEM).
Encapsulation efficiency. To determine the amount of RPV encapsulated in nanoparti-
cles, PLGA/RPV nanoparticles (0.4ml) were applied to an Amicon Ultra centrifugal filter
(Sigma-Aldrich, MO, USA). The filtrate was obtained by spinning the filter at 14000 rpm for
20min at 4°C in an Eppendorf 5417R centrifuge. The amount of free RPV in the filtrate was
measured using a validated reverse-phase HPLC method. The encapsulation efficiency was cal-
culated by the following equation:
%EE ¼ ððW}initial} W}free}Þ =W}initial}Þ X100
where ‘Winitial’ is the amount of RPV/ml of nanoparticle dispersion andWfree is amount of
RPV/ml of filtrate obtained by centrifugation of nanoparticles. All experiments were performed
in triplicate.
High-pressure liquid chromatography (HPLC)
A reverse phase-HPLC method was developed and validated for determination of RPV from
various matrices derived in the topical gel studies. The HPLC apparatus (Shimadzu Corporation,
Columbia, MD) consisted of a pump (LC-20AB), system controller (CBM-20A), degasser unit
(DGU-20A), refrigerated auto-sampler (SIL-20AC), a UV-Vis detector (SPD-20A) and a col-
umn heater (CTO-20A). Samples were run through a C18 pre-column and a Gemini C18
reverse-phase [150mm × 4.5mm (I.D.)] with 5μm particle size packing (Phenomenex, Torrance,
CA). The mobile phase consisted of acetonitrile and 25mMKH2PO4 solution (50:50). For HPLC
analysis, the flow rate of the mobile phase was at 0.6ml/min, column oven was set at 35°C, injec-
tion volume was 20μl and the analysis was carried out at 290nm. The retention time for the RPV
was 12.9min. For standard curve, RPV stock solution (1mg/ml) was prepared in methanol. The
stock solution was diluted with acetonitrile to obtain solutions of various concentrations. A stan-
dard curve was obtained by injecting 0.025–2μg/ml of RPV. The limit of detection for RPV was
8ng/ml. Intra-day and inter-day variability of the analytical method was<10%.
Development of a thermosensitive vaginal gel containing RPV NPs
A thermosensitive vaginal gel containing PLGA/RPV-NPs was prepared as described earlier
[32]. Briefly, the pH of RPV NPs was adjusted to 4.5 with citric acid and sodium citrate. Glyc-
erol (0.225g) was added to PLGA/RPV NPs (10ml) to adjust the osmolarity of nanoparticles.
PLGA/RPV NPs were transferred to a screw-capped bottle and Pluronic F127 (2g) and Pluro-
nic F68 (100mg) were added to PLGA/RPV-NPs with intermittent stirring. The screw-capped
bottle containing PLGA/RPV NPs and Pluronics was stored overnight in the refrigerator to
dissolve Pluronics. On the next day, the dispersions were gently stirred to obtain a homogenous
translucent solution. The solution was observed for signs of nanoparticle aggregation and/or
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phase separation. Thermosensitivity of the gel was confirmed by incubating the gel in a 37°C
water bath. The preparation of thermosensitive gel containing Rhodamine-6G-labeled fluores-
cent PLGA nanoparticles was carried out in a similar manner.
Cell culture
Human cervical (HeLa) cells were purchased from the American Type Culture Collection
(ATCC, Manassas, VA), TZM-bl cells were procured through the NIH AIDS Research and Ref-
erence Reagent Program. HeLa and TZM-bl cells were maintained in complete Dulbecco’s
Modified Eagle’s Media ((DMEM, MediaTech Inc., Manassas, VA) supplemented with 10%
fetal bovine serum (FBS, Hyclone Inc., Utah), 4mM L-glutamine, 100U/ml penicillin and
100μg/ml streptomycin (MP Biomedical Inc., Solon, OH) and maintained in a logarithmic
growth phase. All cells were grown at 37°C and 5% CO2.
In vitro HIV-1 inhibition by RPV NPs and RPV solution
TZM-bl HIV indicator cells were seeded in 24-well plates at a density of 2 x 105 per well. After
24h, the cells were treated with different concentrations of PLGA/RPV NPs and RPV solution
(concentration range: 10μg/ml to 100pg/ml) for 24h. Cells were washed and cultured for 24h in
fresh complete DMEM. Cells were infected with HIV-1 NL4-3 virus (25μl) for 4h and incubated
for an additional 48h. One-Glo reagent (Promega, Madison, WI), supplemented with Triton
X-100 (final concentration 0.01%) was added to inactivate virus and to allow for the measure-
ment of luciferase activity. Results were normalized to the luciferase activity of cells infected
with virus incubated with plain RPMI medium.
RPV LA nanosuspension and RPV plasma level analysis
RPV LA was prepared as previously described [11]. Briefly, a sterile isotonic nanosuspension,
consisting of rilpivirine particles, was prepared by wet nanomilling of the rilpivirine base, sur-
factant, and buffer to ensure neutral pH under aseptic conditions. The median particle size was
200nm. Poloxamer 338 (Pluronics F108), a hydrophilic, nonionic surfactant, was used to
enhance solubility and stabilize the colloidal suspension against aggregation. The final drug
concentration was 300mg/ml.
Plasma was isolated from 0.05–0.1ml peripheral blood samples on EDTA collected from
mouse retro-orbital venous sinus and stored at -80°C until analysis. Plasma samples were ana-
lyzed individually for unchanged rilpivirine by liquid chromatography-tandem mass spectrom-
etry (LC/MS-MS) as described previously [11].
Generation of humanized BLT mice
BLT mice were generated as described previously [19, 23, 26, 27, 47, 48]. Briefly, a 1–2mm
piece of human fetal liver tissue was sandwiched between two pieces of autologous fetal thymus
tissue (Advanced Bioscience Resources, Alameda, CA) under the kidney capsule of sublethally
irradiated (0.250Sv) 6–8 wk old NOD.Cg- Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG; The Jackson
Laboratory, Bar Harbor, ME). Following implantation, mice were transplanted intravenously
with hematopoietic CD34+ stem cells isolated from autologous human fetal liver tissue.
Human immune cell reconstitution was monitored by flow cytometrical analysis of the periph-
eral blood every 2 weeks, as previously described [23, 26, 27, 48]. At the end of experiments,
mice were euthanized by exposure to avertin followed by euthanasia. Mice were maintained at
the Division of Laboratory Animal Medicine, University of North Carolina at Chapel Hill
(UNC-CH).
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Ethics statement
All animal experiments were carried out in accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use Committee guidelines of the
University of North Carolina (protocol number:12–170).
Distribution of nanoparticles in the female reproductive tract
Female humanized-BLT mice were anesthetized with Nembutal. Rhodamine-labeled NPs or
control nanoparticles (without rhodamine) in thermosensitive gel (20μl) was instilled into the
mouse vagina. 1.5h or 24h later, mice were sacrificed and the FRT harvested, fixed in 4% para-
formaldehyde solution (SafeFix, Fisher Science) and embedded in OCT compound (Sakura).
Mouse vaginal frozen sections (5μm) were stained with monoclonal antibody for hCD45
(Dako, mouse IgG1), hCD3 (Thermo Scientific, rabbit IgG), hCD4 (GenWay, Rabbit IgG),
hCD8 (Dako, Mouse IgG1), hCD11c (Leica, mouse IgG2a), mouse IgG1 (Dako), mouse IgG2a
(Dako) or rabbit Ig (Dako) after blocking with Background Sniper (Biocare Medical). The sec-
tions were then stained with either DyLight 488-conjugated donkey anti-mouse IgG or DyLight
488-conjugated donkey anti-rabbit IgG (Jackson Immunoresearch). All sections were finally
counterstained with DAPI (Sigma) and analyzed by confocal microscopy (TCS SP2, Leica).
Treatment and intravaginal exposure of BLT mice to transmitted/founder
HIV-1
For topical administration of PLGA/RPV NP, BLT mice were administered intravaginally with
17.5μg RPV in the form of PLGA/RPV NPs in 20μl thermosensitive gel containing PLGA/RPV
NPs. 1.5h or 24h later, the animals were anesthetized with Nembutal and challenged with
4.5×105 TCID HIV transmission/founder virus HIVRHPA. Control BLT mice (n = 4) received
vehicle or thermosensitive gel with blank nanoparticles, and were challenged with the same
transmission/founder virus.
For systemic administration of RPV LA, female BLT mice received single injection of 15 mg
of nanosuspension intramuscularly. One week later, mice were anesthetized with Nembutal
and intravaginally challenged with transmission/founder viruses (HIVCHO40 3.0×10
5 TCID or
HIVRHPA 4.5×10
5 TCID) or HIVJR-CSF (7.0×10
5 TCID). 3 weeks later, uninfected mice were
challenged vaginally with transmission/founder HIVTHRO (4.0×10
5 TCID).
Viral stocks were generated by transfecting proviral DNA into 293T cells using Lipofecta-
mine 2000 (Invitrogen) and tissue culture infectious units (TCID) were determined using
TZM-bl cells, essentially as we have previously reported [49, 50]. HIV-1 JR-CSF, CHO40,
THRO and RHPA were obtained from Dr. Irving Chen and John Kappes via the AIDS
Research and Reagent Repository Program.
Analysis of HIV-1 infection in humanized BLT mice
Infection of BLT mice with HIV-1 was monitored in peripheral blood by determining levels of
viral RNA in plasma by one-step real-time reverse transcriptase PCR assay, using the following
primers: CATGTTTTCAGCATTATCAGAAGGA, TGCTTGATGTCCCCCCACT, and the
MGB-probe carboxyfluorescein (FAM)-CCACCCCACAAGATTTAAACACCATGCTAA-Q
(nonfluorescent quencher) (Applied Biosystems) (sensitivity of 400 HIV RNA copies/ml). The
percentage of human CD4+ T cells in peripheral blood of BLT mice before challenge (0–2
weeks prior to exposure) and after challenge was determined by flow cytometry with respective
antibodies: hCD45-APC, hCD3-FITC, hCD4-PE and hCD8-PerCP (eBioscience). Flow
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cytometry data were collected using a BD FACSCanto cytometer and analyzed using BD
FACSDiva software. The presence of viral DNA in tissues and peripheral blood collected from
BLT mice was determined by real-time PCR analysis of DNA extracted from 5×104–4×106
cells from harvested tissue (spleen, lymph nodes, bone marrow, liver, lung, female reproductive
tract) or from 15–50μl peripheral blood cells, as previously described [23, 26, 27, 51]; (assay
sensitivity of 10 DNA copies per sample).
Identification of transmitted viruses
Viruses replicating in infected animals were identified by sequence analysis. Viral RNA was
isolated from plasma using QIAamp viral RNA columns (Qiagen) according to the manufac-
turer’s protocol, and cDNA was generated using Superscript III Reverse Transcriptase (Invitro-
gen) with the primer GTGGGTACACAGGCATGTGTGG. cDNA was amplified by nested
PCR using the Expand High Fidelity PCR System (Roche). PCR primers were designed to
anneal in regions with the fewest possible primer mismatches to HIVJR-CSF, HIVCH040,
HIVRHPA and HIVTHRO sequences. Primer sequences were as follows: outer forward primer,
TGCATATTGTGAGTCTGTTACTATGTTTACT; reverse prime CAGGAGCAGATGATA
CAG; inner forward primer, GTAGGACCTACACCTGTCAAC; reverse primer
CCTGCAAAGCTAGGTGAATTGC. Amplified viral DNA was sequenced and compared to
sequences of transmitted/founder viruses.
Statistical analysis
Drug concentrations in plasma over time were compared using Tukey’s multiple comparison
test. Statistical differences between treated and control animals in the efficacy of tested nano-
formulations in protection protecting from vaginal HIV-1 transmission were determined by
log-rank/ Mantel–Cox test. All statistical analyses were performed using GraphPad Prism soft-
ware (version 6).
Supporting Information
S1 Fig. Plasma viral RNA of individual RPV LA treated animals. (A) and controls for 1st
challenge (dotted lines) and 2nd challenge (solid lines)(B) for the experiment depicted in Fig 5.
Arrows indicate time of challenges. Experimental details for individual mouse are indicated in
S3 Table. RNA was quantified by RT PCR with LOQ 400 copies RNA per ml (dash line).
(EPS)
S1 Table. Protection of BLT mice, topically treated with RPV NP in thermosensitive gel,
from vaginal HIV-1 transmission. BLT mice with indicated levels of human CD45+ (hCD45)
cells and human CD3+CD4+ (hCD4) in peripheral blood were vaginally treated with RPV NP,
blank NP or vehicle. At indicated time after the treatment mice were challenged with HIV-
1RHPA. Presence of viral RNA in plasma was monitored over time. Cell-associated DNA was
analyzed in indicated tissues after necropsy. n.a. not analyzed;—negative for viral RNA or
DNA; + positive for viral RNA or DNA; org. thymic organoid, FRT female reproductive tract.
mouse #3 was found dead in the cage; analysis of tissue for cell-associated DNA was not possi-
ble.
(DOCX)
S2 Table. Protection of BLT mice treated with RPV LA from single high dose vaginal chal-
lenge with HIV-1. BLT mice with indicated levels of human CD45+ (hCD45) cells and human
CD3+CD4+ (hCD4) in peripheral blood were treated intramuscularly with RPV LA formula-
tion (RPV LA) or vehicle. One week after the treatment, mice were challenged with HIVCH040.
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Presence of viral RNA in plasma was monitored weekly. Cell-associated DNA was analyzed in
indicated tissue. n.a.: not analyzed;—negative for viral DNA; + positive for viral DNA; org. thy-
mic organoid.
(DOCX)
S3 Table. Protection of BLT mice treated with RPV LA from two high dose vaginal chal-
lenges with HIV-1. BLT mice with indicated levels of human CD45+ (hCD45) cells and
human CD3+CD4+ (hCD4) in peripheral blood were treated intramuscularly with RPV LA for-
mulation (RPV LA) or vehicle. One week after the treatment, mice were challenge with indi-
cated HIV isolates (virus for 1st challenge). Three weeks later 9 mice were challenge with
HIVTHRO (virus for 2
nd challenge). Presence of viral RNA in plasma was monitored weekly.
Viruses in infected mice were identified by sequencing. Cell-associated DNA was analyzed in
indicated tissue. n.a.: not analyzed;—negative for viral DNA; + positive for viral DNA; org. thy-
mic organoid. Notes: mouse # 2R1 died while the 2nd inoculation was being administered,
mouse #2R4 died 3 weeks after 2nd inoculation; mouse #2R5 died 2 weeks after 2nd inoculation.
(DOCX)
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